Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 4/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 4/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24290582 | 0.95 | KDR (0.49) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL27091084 | 0.92 | FGFR3 (0.45) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL2800814 | 0.90 | KDR (0.54) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL24289402 | 0.88 | FGFR3 (0.52) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL2797531 | 0.85 | IRAK1 (0.46) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL27776919 | 0.80 | KDR (0.41) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL2797817 | 0.80 | JAK2 (0.69) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL2798778 | 0.79 | BCL2L1 (0.45) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL2799229 | 0.79 | PIK3CA (0.49) | KDRMETJAK2ABL1JAK1 | |
| SCHEMBL24288950 | 0.78 | ROCK2 (0.42) | FGFR3KDRFGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| EP-2155201-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | FGFR3 538/4885KDR 407/4885FGFR1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.